The medicinal product Pegasys® 180µg, solution for injection, will have limited availability in Belgium until June 2025. Experts of the task force Unavailability recommend the following.
News FAMHP
There are 868 result(s) found based on your search criteria
1-10 from 868 result(s)
Call to professionals responsible for materiovigilance: take part in European Commission survey on electronic instructions for use
The European Commission is considering allowing the use of electronic instructions for use for all devices for professional use. The Commission is therefore launching a survey for healthcare professionals.
Warning: serious adverse reactions when administering the veterinary medicinal product Senvelgo (velagliflozin molecule) to cats suffering from diabetes
The Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA), having analysed recent reports on diabetic ketoacidosis associated with Senvelgo use, now issues recommendations.
PRAC July 2024 – New recommendations for GLP-1 receptor agonists and direct healthcare professional communication for glatiramer acetate containing products
During its July 2024 meeting, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency issued new recommendations for GLP-1 receptor agonists and agreed a direct healthcare professional communication for glatiramer acetate containing products.
Improving the availability of in vitro diagnostics: European measures
New measures published in the European Union’s Official Journal come into effect to improve the availability of in vitro diagnostics, for patients and healthcare providers.
PRAC June 2024 – PRAC started review of painkiller metamizole and identified risk of secondary malignancies of T-cell origin with CAR T-cell medicines
During its June 2024 meeting, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency started a review of the painkiller metamizole and identified a risk of secondary malignancies of T-cell origin with CAR T- cell medicines.
Kexxtone: suspension of marketing authorisation and recall of all batches
The EMA's Committee for Veterinary Medicinal Products (CVMP) recommends suspending the marketing authorisation for Kexxtone 32.4 g continuous-release intraruminal device for cattle (EU/2/12/145/001-003) and recalling batches from the market.
The European Medicines Regulatory Network is now a WHO Listed Authority
The European Medicines Regulatory Network (EMRN), of which the FAMHP is part, has been designated as WHO Listed Authority by the World Health Organisation.
Warning concerning non-compliant/illegal products intended for men and sold in tobacco shops
Following a control in ten tobacco shops in the Mouscron area, the FAMHP is warning against the purchase of non-compliant/illegal products that may present a health risk.
Overview of FAMHP achievements and accomplishments in the context of the Belgian presidency
From 1 January 2024 to 30 June 2024, Belgium chaired the Council of the European Union, the body in which the 27 member states set the political direction and priorities of the European Union. During this period, the FAMHP organised over 20 events and meetings to promote cooperation and dialogue among member states and with European institutions. In addition, the FAMHP provided expertise to many important European initiatives. Time for a recap.